In a report released today, Cheng Li from Oppenheimer maintained a Buy rating on Vaxart (VXRT – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $0.82.
Currently, the analyst consensus on Vaxart is a Moderate Buy with an average price target of $3.25.
The company has a one-year high of $1.54 and a one-year low of $0.52. Currently, Vaxart has an average volume of 2.11M.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vaxart (VXRT) Company Description:
Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.
Read More on VXRT:
- Biotech Alert: Searches spiking for these stocks today
- Vaxart reports inducement grants under Nasdaq listing rule
- Vaxart: Vaccine platform may be effective for HPV-related cervical dysplasia
- Brinker upgraded, Snowflake downgraded: Wall Street’s top analyst calls
- Vaxart rallies 6% to 63c after bullish Opco initiation with $4 target
